Earlier, Relmada Therapeutics Announced Publication Of Results From The Phase 3 Reliance I Study of REL-1017 In The Journal Of Clinical Psychiatry
Earlier, Relmada Therapeutics Announced Publication Of Results From The Phase 3 Reliance I Study of REL-1017 In The Journal Of Clinical Psychiatry
Relmada Therapeutics, Inc. (NASDAQ:RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the publication of REL-1017 clinical data from the Reliance I Study in the peer-reviewed journal, The Journal of Clinical Psychiatry. The article is titled, "Efficacy and Safety of Esmethadone (REL-1017) in Patients with Major Depressive Disorder and Inadequate Response to Standard Antidepressants: A Phase 3 Randomized Controlled Trial", and is available online at Link To Title.
Relmada Therapeutics, Inc.（纳斯达克:RLMD）是一家专注于治疗中枢神经系统疾病的晚期生物技术公司，今天宣布在同行评议的期刊《临床精神病学杂志》中发布了来自Reliance I研究的REL-1017临床数据。该文章的题目是“Efficacy and Safety of Esmethadone（REL-1017）in Patients with Major Depressive Disorder and Inadequate Response to Standard Antidepressants: A Phase 3 Randomized Controlled Trial”，在线可链接至标题。